Our journey started in 2006 when Organon (which was part of Akzo Nobel a Dutch chemical giant) decided to continue and further expand their business in Pakistan by selecting OBS as their preferred strategic partner.
From a humble beginning in 1963 as Organon Pakistan, today OBS Healthcare has become a name associated with quality medicine throughout Pakistan with strong presence in Gynecology (Contraception, Infertility and Menopause therapy), Psychiatry and Anesthesiology.
After achieving a consistent leading position in most of the specialized therapeutic areas, in 2007 OBS Pharma was launched through which OBS entered into first line therapeutic areas like Anti-Infectives, Anti-Ulcerants & Heamatinics with an aim to provide quality drugs at relatively affordable prices.
In April 2008, OBS achieved yet another milestone when Merck & Co, Inc., USA became OBS’s strategic partner for their business in Pakistan. In doing this, OBS acquired Merck Sharp & Dohme Pakistan Ltd. (MSD Pakistan) operations including the manufacturing facility under the name OBS Pakistan. This company is well known for its expertise in areas like Cardiology, Neuropsychiatry, Infectious Diseases, Respiratory Disorders, Ophthalmology, Bone Disorders and Endocrinology.
In continuation of its rapid pace of expansions in June 2009, OBS further signed a strategic alliance with Merck & Co. Inc., USA to acquire certain MSD brands in Sri Lanka. This was the first step for OBS in the international arena followed by which it looks to rapidly expand its operations in other South East Asian and CIS countries including Vietnam, Philippines, Myanmar and Uzbekistan.
Realizing the significance of research and development and its need in Pakistan, in 2009 OBS took another pioneering initiative by launching Aklima Clinical Research which is a Clinical Research Organisation (CRO) with a mission to be the partner of choice for Clinical Research Services and Trial Management in Pakistan. Aklima Clinical Research today is functioning as a CRO offering the capability of conducting Phase I – IV Clinical Trials having the capacity to support related Trial Management Services. As Clinical Trials take off in Pakistan, there will also be a need for skilled monitors. Aklima Clinical Research has embarked on a joint venture with Norton Audits, Inc., USA for exclusively conducting a training program for CRAs as well as Clinical Investigators. Additional services include provision of data management services for all information transfer pertaining to Clinical Trials.
In December 2010, MSD as a natural progression to its business strategy and considering the successful track record of its strategic partner in Pakistan made OBS the custodian for their Schering Plough business in Pakistan mainly specializing in the field of Gastroenterology and Cardiology.
Overall in this brief span of 5 years, OBS has reached to the top 20 Pharma companies in Pakistan out of 695 registered companies.